2016ASCOMET通路进展研究分析.ppt

* BID, twice daily; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; QD, once daily; RP2D, recommended Phase II dose. * * * * * * * * * * * 美国加利福尼亚大学医学院Sai-Hong Ignatius Ou教授 MET exon 14 skipping (METex14) has recently been described a potential driver alteration in lung cancer targetable by MET tyrosine kinase inhibitors (TKIs) (PMID:. However, a large series of lung cancer cases harboring METex14 alterations has not been reported hybridizationg capture of at least 3769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in